http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022265667-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0188cf0f35f6fb550c7592adfe8aca18 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 |
| filingDate | 2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31a8d0739785f569039b9eb790425ac |
| publicationDate | 2022-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022265667-A1 |
| titleOfInvention | Etifoxine for use in the treatment of diseases related to activated mast cells |
| abstract | Etifoxine, or a pharmaceutically acceptable derivative thereof, can be used for the treatment of a disease related to activated mast cells in a subject, preferably a human. Furthermore, a pharmaceutical composition containing Etifoxine, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable excipient can be used for the treatment of a disease related to activated mast cells. An in vitro or ex-vivo method of inhibiting mast cell activation, involves contacting a cell with Etifoxine, or a pharmaceutically acceptable derivative thereof. |
| priorityDate | 2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2606.